Skip to main content

REVIEW article

Front. Oncol.
Sec. Genitourinary Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1394260

Advances in molecular basis of response to immunotherapy for penile cancer: better screening of responders

Provisionally accepted
Da-Ming Xu Da-Ming Xu 1Ling-Xiao Chen Ling-Xiao Chen 2Xiao-Yu Zhuang Xiao-Yu Zhuang 3Hui Han Hui Han 1*Miao Mo Miao Mo 2*
  • 1 Sun Yat-sen University Cancer Center, Guangzhou, China
  • 2 Xiangya Hospital, Central South University, Changsha, Hunan Province, China
  • 3 Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    Penile cancer is a rare malignant tumor of the male urinary system. The treatment benefit of standard first-line chemotherapy is not ideal for patients with locally advanced or metastatic lymph nodes. Immunotherapy has brought new treatment strategies and opportunities for patients with penile cancer. At present, clinical studies on immunotherapy for penile cancer have been reported, and the results show that it is effective but not conclusive. With the development of immunotherapy and the progress of molecular research technology, we can better screen the immunotherapy response population and explore new combination treatment regimens to evaluate the best combination regimen and obtain the optimal treatment options, which is also an important research direction for the immunotherapy of penile cancer in the future.

    Keywords: Penile Cancer, Immunotherapy, biomarker, Sensitivity, Resistance

    Received: 05 Mar 2024; Accepted: 05 Jul 2024.

    Copyright: © 2024 Xu, Chen, Zhuang, Han and Mo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hui Han, Sun Yat-sen University Cancer Center, Guangzhou, China
    Miao Mo, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.